Are there any other Bacillus strains that can be used for Staphylococcus aureus decolonization?

Recommendation: Bacillus strains for S. aureus decolonization

Use Bacillus subtilis (particularly MB40) if pursuing probiotic-based S. aureus decolonization; no other Bacillus strain has human RCT evidence of reducing S. aureus colonization, and standard-of-care remains mupirocin (± chlorhexidine) per guidelines. 1, 2

• Guideline-first (mortality/morbidity/QoL priority)

  • For surgical patients colonized with S. aureus: decolonize with intranasal mupirocin ± chlorhexidine bathing; add vancomycin to prophylaxis for MRSA carriers in selected high-risk surgeries. No probiotic is recommended in guidelines. 1
  • Rationale: Proven reduction in SSIs, which drive morbidity, mortality, and QoL loss. 1

• Evidence on Bacillus strains

  • Human RCT: B. subtilis MB40, 250 mg daily ×30 days, significantly reduced S. aureus colonization in stool (≈97%) and nares (≈65%) without safety signals or major microbiome disruption. This is the highest-quality, most recent human evidence supporting a Bacillus strain for decolonization. 2
  • Human observational/mechanistic: Dietary Bacillus producing fengycins interfered with S. aureus quorum sensing (Agr) and abolished colonization in a Thai cohort (pathway-level plausibility). 3
  • Preclinical/experimental:
    • B. subtilis-derived peptides (e.g., surfactin variants; uncharacterized peptide) disrupt S. aureus Agr and biofilms, enhancing antibiotic susceptibility—strain-specific (e.g., B. subtilis 6D1). Not validated in human decolonization. 4
    • Recombinant B. subtilis expressing mSEB reduced intestinal S. aureus in mice via immune mechanisms; not a clinical product. 5

• Practical algorithm

  1. If surgical decolonization is the goal:
     • Do not replace guideline therapy. Use intranasal mupirocin ± chlorhexidine; consider targeted vancomycin prophylaxis for MRSA carriers as specified. 1
  2. If seeking probiotic adjunct/alternative outside perioperative guidelines:
     • Choose B. subtilis MB40 (only Bacillus strain with human RCT efficacy for S. aureus decolonization). Avoid unproven Bacillus strains. 2
  3. Monitor outcomes that matter:
     • Track SSI rates and invasive S. aureus infections; if using probiotics, do so as adjuncts, not substitutes for proven measures in high-risk settings. 1

• Nuances and caveats

  • Probiotics are not guideline-endorsed for pre-op decolonization; use MB40 evidence cautiously, especially where SSIs drive mortality/morbidity. 1, 2
  • Strain specificity is critical—benefits seen with MB40 cannot be extrapolated to other Bacillus strains or generic “Bacillus” products. 2, 4
  • Experimental strains (e.g., 6D1; recombinant mSEB B. subtilis) and peptide fractions are promising but not clinically deployable. 4, 5
  • Decolonization remains central to infection prevention but overuse of antimicrobials raises resistance concerns; probiotics may help in the future, but current standard remains topical agents per guideline. 6, 7

• Common pitfalls to avoid

  • Substituting probiotics for mupirocin/chlorhexidine in high-risk surgical patients. Outcome risk: higher SSI, morbidity/mortality. 1
  • Using non-MB40 Bacillus products assuming class effect. Evidence is strain-specific. 2
  • Expecting probiotics to treat active infection; they are for colonization control only. For bacteremia or invasive disease, follow evidence-based antibiotic therapy. 8